Mark Ragains

Mark Ragains has extensive work experience in the field of pharmaceutical science. Mark started their career in 2005 at Amgen, where they held positions as a Scientist and eventually became a Senior Scientist. During their time at Amgen, they gained experience in small-molecule preformulation and CMC activities. Mark also supported the development of sustained-release formulations and identified suitable formulations for liquid-filled solid dosage forms.

In 2011, Mark joined Alcon, a Novartis company, where they initially served as an Assistant Director and later as an Associate Director. In these roles, they managed the Preformulation Group and implemented robotic technology for high-throughput screening. Mark also provided consultation and troubleshooting support for ocular projects and implemented data processing using custom Mathematica code.

In 2015, Mark joined Genentech Carlifornia USA as a Scientist. Mark worked on preformulation of small-molecules for API's targeting oral or intravenous delivery in the clinic. Mark'sresponsibilities included project support from late-discovery through early development and Phase 1. Mark also contributed to CMC activities such as tech transfer, batch record review, and authoring relevant sections of IMPD and CTA.

Most recently, in 2021, Mark joined Turn Biotechnologies as a Principal Scientist. Currently, they hold the position of Principal Pharmaceutical Scientist at Varda Space Industries starting from March 2023.

Throughout their career, Mark has demonstrated expertise in preformulation and project support for pharmaceutical development.

Mark Ragains has a Doctor of Philosophy (Ph.D.) in Physical Organic Chemistry from the University of California, Santa Cruz.